Avalo Therapeutics (AVTX) Share-based Compensation (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Share-based Compensation data on file, last reported at $779000.0 in Q1 2026.

• Quarterly Share-based Compensation changed N/A year-over-year to $779000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 304.93% YoY) and the FY2025 annual result came in at $510000.0, changed N/A from the prior year.
• Share-based Compensation advanced to $779000.0 in Q1 2026, from -$8.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.6 million in Q3 2025 to a low of -$8.6 million in Q4 2025.
• A 5-year average of $880000.0 and a median of $777500.0 in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 266.85% — and 2024, when it sank 170.44%.
• Tracing AVTX's Share-based Compensation over 5 years: stood at $843000.0 in 2022, then decreased by 7.95% to $776000.0 in 2023, then plunged by 181.06% to -$629000.0 in 2024, then sank by 1267.73% to -$8.6 million in 2025, then jumped by 109.05% to $779000.0 in 2026.
• The last three Share-based Compensation figures came in at $779000.0 (Q1 2026), -$8.6 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.